SG11201903835WA - Antibodies directed against programmed death- 1 (pd-1) - Google Patents
Antibodies directed against programmed death- 1 (pd-1)Info
- Publication number
- SG11201903835WA SG11201903835WA SG11201903835WA SG11201903835WA SG11201903835WA SG 11201903835W A SG11201903835W A SG 11201903835WA SG 11201903835W A SG11201903835W A SG 11201903835WA SG 11201903835W A SG11201903835W A SG 11201903835WA SG 11201903835W A SG11201903835W A SG 11201903835WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- suite
- california
- november
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#1110111101110101011111 vu 1101 0 0111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/085468 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) Cl 2N 15/13 (2006.01) Published: C07K 16/28 (2006.01) — with international search report (Art 2 1 (3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/059618 amendments (Rule 48.2(h)) (22) International Filing Date: 01 November 2017 (01.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,128 01 November 2016 (01.11.2016) US 62/427,777 29 November 2016 (29.11.2016) US (71) Applicants: ANAPTYSBIO, INC. [US/US]; 10421 Pacif- ic Center Court, Suite 200, San Diego, California 92121 (US). TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). (72) Inventors: KING, David J.; 310 Cole Ranch Road, Encini- _ tas, California 92024 (US). KEHRY, Marilyn; 10440 Rock Creek Drive, San Diego, California 92131 (US). HUANG, Baochuan; c/o Tesaro, Inc., 1000 Winter Street North, Suite = 3300, Waltham, Massachusetts 02451 (US). = Agent: ESPINO, Christine, G. et al.; Proskauer Rose = (74) _ LLP, One International Place, Boston, Massachusetts 02110 — = (US). Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, — MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — 1-1 GC MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). , tD iv 1 1 in ot (54) Title: ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH- 1 (PD-1) ---- (57) : The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin GC heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related 0 nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive N to PD-1 inhibition, such as cancer or an infectious disease. C
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662416128P | 2016-11-01 | 2016-11-01 | |
US201662427777P | 2016-11-29 | 2016-11-29 | |
PCT/US2017/059618 WO2018085468A1 (en) | 2016-11-01 | 2017-11-01 | Antibodies directed against programmed death- 1 (pd-1) |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903835WA true SG11201903835WA (en) | 2019-05-30 |
Family
ID=62075647
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903835WA SG11201903835WA (en) | 2016-11-01 | 2017-11-01 | Antibodies directed against programmed death- 1 (pd-1) |
SG10201913306WA SG10201913306WA (en) | 2016-11-01 | 2017-11-01 | Antibodies directed against programmed death- 1 (pd-1) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913306WA SG10201913306WA (en) | 2016-11-01 | 2017-11-01 | Antibodies directed against programmed death- 1 (pd-1) |
Country Status (13)
Country | Link |
---|---|
US (2) | US11155624B2 (en) |
EP (2) | EP3666794A1 (en) |
JP (1) | JP2019533458A (en) |
KR (1) | KR20190101364A (en) |
CN (1) | CN110049777A (en) |
AU (1) | AU2017354070A1 (en) |
BR (1) | BR112019008859A2 (en) |
CA (1) | CA3041684C (en) |
IL (2) | IL266229A (en) |
MA (2) | MA46724A (en) |
MX (1) | MX2019005117A (en) |
SG (2) | SG11201903835WA (en) |
WO (1) | WO2018085468A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9815897B2 (en) * | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
CN114591433A (en) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
KR20190101364A (en) | 2016-11-01 | 2019-08-30 | 테사로, 인코포레이티드 | Antibody Against Probable Death-1 (PD-1) |
ES2945745T3 (en) * | 2017-01-09 | 2023-07-06 | Tesaro Inc | Methods of treating cancers with anti-PD-1 antibodies |
AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
US11730725B2 (en) | 2017-09-26 | 2023-08-22 | Tesaro, Inc. | Niraparib formulations |
MX2020003770A (en) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Combination therapies for treating cancer. |
CN111182923A (en) | 2017-10-06 | 2020-05-19 | 特沙诺有限公司 | Combination therapy and uses thereof |
TW202024638A (en) | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | Methods of treating cancer |
CN113330007A (en) | 2018-10-03 | 2021-08-31 | 特沙诺有限公司 | Crystalline forms of nilapali free base |
EP3860981B1 (en) | 2018-10-03 | 2023-11-29 | Tesaro, Inc. | Niraparib salts |
AU2020207132A1 (en) | 2019-01-11 | 2021-06-24 | Eli Lilly And Company | TIM-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer |
EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
TW202120550A (en) | 2019-08-08 | 2021-06-01 | 日商小野藥品工業股份有限公司 | Bispecific protein |
KR20220129548A (en) | 2019-12-18 | 2022-09-23 | 테사로, 인코포레이티드 | Biopharmaceutical compositions and related methods |
BR112022014562A2 (en) * | 2020-01-28 | 2022-09-13 | Glaxosmithkline Ip Dev Ltd | COMBINATION TREATMENTS, USES AND METHODS THEREOF |
WO2021169984A1 (en) * | 2020-02-24 | 2021-09-02 | 甫康(上海)健康科技有限责任公司 | Anti-coronavirus application of poly adp ribose polymerase inhibitor |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
DK0557459T3 (en) | 1990-11-13 | 1997-12-15 | Immunex Corp | Bifunctional, selectable fusion genes |
AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
CA2414331C (en) | 2000-06-28 | 2011-11-29 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
FR2814642B1 (en) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER |
JP3871326B2 (en) | 2000-11-15 | 2007-01-24 | 小野薬品工業株式会社 | PD-1-deficient mice and uses thereof |
AR036993A1 (en) | 2001-04-02 | 2004-10-20 | Wyeth Corp | USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS |
BR0208637A (en) | 2001-04-02 | 2004-12-07 | Wyeth Corp | Pd-1, a b7-4 receptor, and uses thereof |
US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
JP4488740B2 (en) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Agents that modulate immune cell activation and methods of use thereof |
SI2206517T1 (en) | 2002-07-03 | 2023-12-29 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
KR101339628B1 (en) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
KR101514463B1 (en) | 2005-06-08 | 2015-04-28 | 다나-파버 캔서 인스티튜트 인크. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
AU2006261127B2 (en) | 2005-06-17 | 2012-03-15 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
EP2889309B1 (en) | 2006-03-03 | 2017-12-27 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of pd-1 or pd-l1 |
NZ596237A (en) | 2006-12-27 | 2012-07-27 | Dana Farber Cancer Inst Inc | Compositions and methods for the treatment of infections and tumors |
RS51780B (en) | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
BRPI0807952A2 (en) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Somatic Hypermutation Systems |
JP2010524846A (en) * | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | Anti-sclerostin antibody |
EP2162472B1 (en) | 2007-05-30 | 2013-02-27 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
KR101653548B1 (en) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-4-3--3--2--7- Pharmaceutically acceptable salts of 2-4-3-piperidin-3-ylphenyl-2H-indazole-7-carboxamide |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
WO2010001617A1 (en) | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
JP2012501670A (en) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | PD-1-specific antibodies and uses thereof |
CA2736816C (en) | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
MX2011003195A (en) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor. |
KR101050829B1 (en) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody |
DK2370593T3 (en) | 2008-11-28 | 2016-07-04 | Univ Emory | A method for determining the effect of PD-1 Antagonists |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
AU2010343056A1 (en) | 2009-12-29 | 2012-08-02 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
WO2011110604A1 (en) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US20130035472A1 (en) | 2010-03-17 | 2013-02-07 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
CA2805564A1 (en) | 2010-08-05 | 2012-02-09 | Stefan Jenewein | Anti-mhc antibody anti-viral cytokine fusion protein |
US20130217656A1 (en) | 2010-08-12 | 2013-08-22 | Beth Israel Deaconess Medical Center Inc | Methods and compositions for diagnosing and treating lupus |
US20130310266A1 (en) | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
CN110038135B (en) | 2011-03-17 | 2021-03-05 | 伯明翰大学 | Redirected immunotherapy |
KR20190116563A (en) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
CN107519486B (en) | 2011-06-24 | 2021-06-11 | 台北荣民总医院 | Method for enhancing immune response in the treatment of infectious and malignant diseases |
EP2742953B1 (en) | 2011-08-11 | 2021-09-22 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
CA3213528A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
US20150079192A1 (en) | 2012-05-21 | 2015-03-19 | Marv Enterprises, LLC | Treatment of cancer by manipulating the immune system |
WO2013174997A1 (en) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies |
CA2874144C (en) | 2012-05-31 | 2023-12-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
US9815897B2 (en) * | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
MY184154A (en) * | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
TWI697500B (en) | 2014-03-14 | 2020-07-01 | 瑞士商諾華公司 | Antibody molecules to lag-3 and uses thereof |
EP3590967A1 (en) | 2014-03-24 | 2020-01-08 | Cancer Research Technology Limited | Modified antibodies containing modified igg2 domains which elicit agonist properties and use thereof |
LT3157956T (en) | 2014-06-19 | 2020-05-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
CN107074947B (en) | 2014-08-05 | 2021-04-09 | 马布奎斯特公司 | Immunity agent binding to PD-1 |
ES2774448T3 (en) | 2014-10-03 | 2020-07-21 | Novartis Ag | Combination therapies |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
MA41218A (en) | 2014-12-19 | 2017-10-24 | Advaxis Inc | LISTERIA VACCINE COMBINATION WITH ANTI-OX40 OR ANTI-GITR ANTIBODIES |
US10239942B2 (en) | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
LT3240801T (en) | 2014-12-31 | 2021-02-25 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
CA3081058C (en) | 2015-01-16 | 2024-02-20 | Academia Sinica | Linker units and their uses in configuring pharmaceutical molecules |
MA41463A (en) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) |
MA41867A (en) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3) |
EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
KR20190101364A (en) | 2016-11-01 | 2019-08-30 | 테사로, 인코포레이티드 | Antibody Against Probable Death-1 (PD-1) |
AU2018205401A1 (en) | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
ES2945745T3 (en) * | 2017-01-09 | 2023-07-06 | Tesaro Inc | Methods of treating cancers with anti-PD-1 antibodies |
MX2020003770A (en) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Combination therapies for treating cancer. |
-
2017
- 2017-11-01 KR KR1020197015225A patent/KR20190101364A/en not_active Application Discontinuation
- 2017-11-01 MA MA046724A patent/MA46724A/en unknown
- 2017-11-01 CN CN201780075865.6A patent/CN110049777A/en active Pending
- 2017-11-01 MA MA049863A patent/MA49863A/en unknown
- 2017-11-01 JP JP2019522701A patent/JP2019533458A/en not_active Withdrawn
- 2017-11-01 US US16/346,485 patent/US11155624B2/en active Active
- 2017-11-01 AU AU2017354070A patent/AU2017354070A1/en not_active Abandoned
- 2017-11-01 MX MX2019005117A patent/MX2019005117A/en unknown
- 2017-11-01 BR BR112019008859A patent/BR112019008859A2/en not_active IP Right Cessation
- 2017-11-01 EP EP20150603.7A patent/EP3666794A1/en not_active Withdrawn
- 2017-11-01 CA CA3041684A patent/CA3041684C/en active Active
- 2017-11-01 SG SG11201903835WA patent/SG11201903835WA/en unknown
- 2017-11-01 SG SG10201913306WA patent/SG10201913306WA/en unknown
- 2017-11-01 WO PCT/US2017/059618 patent/WO2018085468A1/en unknown
- 2017-11-01 EP EP17867513.8A patent/EP3534950A4/en not_active Withdrawn
-
2019
- 2019-04-24 IL IL266229A patent/IL266229A/en unknown
-
2021
- 2021-02-09 IL IL280766A patent/IL280766A/en unknown
- 2021-09-27 US US17/486,709 patent/US20220089739A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220089739A1 (en) | 2022-03-24 |
CA3041684A1 (en) | 2018-05-11 |
IL280766A (en) | 2021-04-29 |
WO2018085468A1 (en) | 2018-05-11 |
BR112019008859A2 (en) | 2019-07-09 |
US11155624B2 (en) | 2021-10-26 |
MA49863A (en) | 2020-06-17 |
AU2017354070A1 (en) | 2019-05-16 |
EP3534950A1 (en) | 2019-09-11 |
EP3534950A4 (en) | 2020-05-06 |
EP3666794A1 (en) | 2020-06-17 |
US20190256600A1 (en) | 2019-08-22 |
MX2019005117A (en) | 2019-10-21 |
IL266229A (en) | 2019-06-30 |
CA3041684C (en) | 2023-09-26 |
CN110049777A (en) | 2019-07-23 |
SG10201913306WA (en) | 2020-02-27 |
JP2019533458A (en) | 2019-11-21 |
MA46724A (en) | 2021-04-21 |
KR20190101364A (en) | 2019-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
SG11201810509PA (en) | Anti-pd-l1 antibodies | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture |